From our Partners at Innovative Rx Strategies

July 2, 2024

Big news continues in the GLP-1 space. The first generic medication of a GLP-1 launched in June 2024, as Victoza goes generic. With GLP-1s busting budgets across the country, this may seem like welcome news.  But the promise of savings is not a given. While generic medications coming to market typically offer savings relief, it isn’t as straightforward in this case. So, let’s examine liraglutide.

Competition Drives Savings

On June 24, an authorized generic of Victoza was launched. Authorized generics aren’t the same as typical generics. The brand name manufacturer has allowed the early entry of a generic in the market. In this case, liraglutide is still being manufactured by the same manufacturer of Victoza but then marketed and released by a second manufacturer.

While this process has led to some savings in the list price, until additional generic products are released, the complexity of PBM contract designation, rebates and lack of competition is limiting savings greatly. While legal battles continue, it is anticipated that up to 10 additional true generics may come to market in December of 2024. That is when we will be able to better appreciate the savings with this new generic agent.

Utilization Limits

Victoza is one of the least used GLP-1 agents for the treatment of diabetes. When it came to market, it quickly picked up speed, but it is a once-a-day injection. As newer treatments like Ozempic and Mounjaro came to market as weekly injections with larger weight loss promises, Victoza faded into the background.

Today, Victoza only has 4.6% of the GLP-1 market share for diabetes treatment. However, it can still make an impact on the management of diabetes. And it has been proven and approved to reduce cardiovascular disease in patients with diabetes and cardiovascular disease.

Indications

While GLP-1s were first used for diabetes management, it is their impact and indication for weight loss that really started the GLP-1 frenzy we see today. Liraglutide is also the active ingredient in Saxenda which is a brand name product approved for weight loss.

The weight loss impact of liraglutide is less than 50% of the other agents on the market. The dosing of liraglutide for weight loss is also higher than the dosing when used for diabetes. The smaller impact and higher dose needs will limit any potential savings when used in the weight loss space at this time.

Despite the barriers in this space, liraglutide is still a great choice for the management of diabetes when it comes to hemoglobin A1c lowering with cardiovascular benefit. Once weekly diabetes agents offer convenience and additional weight loss potential. However, neither of these factors are vital for all patients when it comes to GLP-1 impact on diabetes management.

What is next?

Victoza goes generic, but what is next? As additional generics hit the market in the next 6-12 months, opportunities exist for savings. However, plan sponsors must be nimble in their approach to take advantage of these savings. They should also work with pharmacy consultants with clinical pharmacists on staff, like those at Innovative Rx Strategies. Please contact us to learn more about how to leverage this breaking news in the GLP-1 space.

Go to the original post.

About Innovative Rx Strategies

In addition to their valued partnership with Apex Benefits, the pharmacist-led team at Innovative Rx Strategies serves organizations across the United States who are serious about reducing their pharmacy benefits costs. No other independent pharmacy benefits consulting firm offers the same level of proficiency across the pharmacy, PBM and health care industries. They do all the heavy lifting and hold PBMs accountable to make sure clients receive the greatest value possible from their pharmacy benefits plans.

Learn more about the Innovative Rx Strategies Team
Pharmacy Benefits: Victoza Goes Generic

More Pharmacy Benefits Insights

  • February 19, 2024

    Employer Impact Report: Explore The Landscape

    GLP-1s for weight loss will impact benefit plans for years to come. Explore the GLP-1 landscape in the second session of the Employer Impact Report on Weight Loss Drugs. This pharmacist-led webinar will help employers build a strategy around high-cost …

  • January 25, 2024

    Employer Impact Report: History of GLP-1s

    Drugs for diabetes and weight loss are a part of the cultural conversation today. But how did we get there. Examine the history of GLP-1s.

  • December 12, 2023

    Health Care Cost Trends for 2024

    Health care costs are on the rise. We are breaking down three health care cost trends for 2024 and how employers can mitigate their financial risk.